Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
RHHVF's Cash-to-Debt is ranked lower than
74% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. RHHVF: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
RHHVF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.18 Max: N/A
Current: 0.41
Equity-to-Asset 0.31
RHHVF's Equity-to-Asset is ranked lower than
86% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. RHHVF: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
RHHVF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.38 Max: 0.59
Current: 0.31
0.1
0.59
Interest Coverage 20.45
RHHVF's Interest Coverage is ranked lower than
64% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.12 vs. RHHVF: 20.45 )
Ranked among companies with meaningful Interest Coverage only.
RHHVF' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 12.43 Max: N/A
Current: 20.45
Piotroski F-Score: 9
Altman Z-Score: 3.79
Beneish M-Score: -2.75
WACC vs ROIC
6.26%
27.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 27.82
RHHVF's Operating Margin % is ranked higher than
91% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. RHHVF: 27.82 )
Ranked among companies with meaningful Operating Margin % only.
RHHVF' s Operating Margin % Range Over the Past 10 Years
Min: 25.03  Med: 28.89 Max: 33.69
Current: 27.82
25.03
33.69
Net Margin % 18.93
RHHVF's Net Margin % is ranked higher than
85% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. RHHVF: 18.93 )
Ranked among companies with meaningful Net Margin % only.
RHHVF' s Net Margin % Range Over the Past 10 Years
Min: 15.87  Med: 18.83 Max: 22.97
Current: 18.93
15.87
22.97
ROE % 45.35
RHHVF's ROE % is ranked higher than
95% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. RHHVF: 45.35 )
Ranked among companies with meaningful ROE % only.
RHHVF' s ROE % Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 45.35
19.94
102.95
ROA % 12.65
RHHVF's ROA % is ranked higher than
86% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. RHHVF: 12.65 )
Ranked among companies with meaningful ROA % only.
RHHVF' s ROA % Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.65
10.33
17.58
ROC (Joel Greenblatt) % 62.96
RHHVF's ROC (Joel Greenblatt) % is ranked higher than
89% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. RHHVF: 62.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RHHVF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 52.39  Med: 64.84 Max: 84.52
Current: 62.96
52.39
84.52
3-Year Revenue Growth Rate 1.40
RHHVF's 3-Year Revenue Growth Rate is ranked lower than
65% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. RHHVF: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RHHVF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78  Med: 1.5 Max: 390.8
Current: 1.4
-78
390.8
3-Year EBITDA Growth Rate -2.20
RHHVF's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. RHHVF: -2.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RHHVF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -88.5  Med: 2.7 Max: 268.9
Current: -2.2
-88.5
268.9
3-Year EPS without NRI Growth Rate -4.90
RHHVF's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. RHHVF: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RHHVF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.9  Med: 5.8 Max: 340.9
Current: -4.9
-4.9
340.9
GuruFocus has detected 6 Warning Signs with Roche Holding AG $RHHVF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RHHVF's 10-Y Financials

Financials (Next Earnings Date: 2017-07-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with RHHVF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:BAYRY » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group has been bolstered by the acquisition of Ventana in 2008. Oncology products account for more than 60% of pharmaceutical sales, and professional diagnostics for more than half of diagnostic-related sales.

Ratios

vs
industry
vs
history
PE Ratio 22.73
RHHVF's PE Ratio is ranked higher than
64% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.26 vs. RHHVF: 22.73 )
Ranked among companies with meaningful PE Ratio only.
RHHVF' s PE Ratio Range Over the Past 10 Years
Min: 13.05  Med: 19.65 Max: 29.42
Current: 22.73
13.05
29.42
Forward PE Ratio 15.60
RHHVF's Forward PE Ratio is ranked higher than
57% of the 109 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. RHHVF: 15.60 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.73
RHHVF's PE Ratio without NRI is ranked higher than
63% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.28 vs. RHHVF: 22.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
RHHVF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.05  Med: 19.65 Max: 29.2
Current: 22.73
13.05
29.2
Price-to-Owner-Earnings 16.72
RHHVF's Price-to-Owner-Earnings is ranked higher than
75% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.92 vs. RHHVF: 16.72 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RHHVF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.41  Med: 15.2 Max: 23.23
Current: 16.72
9.41
23.23
PB Ratio 9.01
RHHVF's PB Ratio is ranked lower than
89% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. RHHVF: 9.01 )
Ranked among companies with meaningful PB Ratio only.
RHHVF' s PB Ratio Range Over the Past 10 Years
Min: 2.59  Med: 11.33 Max: 22.21
Current: 9.01
2.59
22.21
PS Ratio 4.30
RHHVF's PS Ratio is ranked lower than
64% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. RHHVF: 4.30 )
Ranked among companies with meaningful PS Ratio only.
RHHVF' s PS Ratio Range Over the Past 10 Years
Min: 2.38  Med: 3.98 Max: 5.46
Current: 4.3
2.38
5.46
Price-to-Free-Cash-Flow 21.74
RHHVF's Price-to-Free-Cash-Flow is ranked higher than
55% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.25 vs. RHHVF: 21.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RHHVF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.6  Med: 17.18 Max: 37.16
Current: 21.74
8.6
37.16
Price-to-Operating-Cash-Flow 14.50
RHHVF's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.28 vs. RHHVF: 14.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RHHVF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 13.51 Max: 22.22
Current: 14.5
6.98
22.22
EV-to-EBIT 16.89
RHHVF's EV-to-EBIT is ranked higher than
57% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.12 vs. RHHVF: 16.89 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHVF' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 14 Max: 19.8
Current: 16.89
7.5
19.8
EV-to-EBITDA 13.04
RHHVF's EV-to-EBITDA is ranked higher than
61% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.99 vs. RHHVF: 13.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHVF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 11.85 Max: 15.7
Current: 13.04
6.3
15.7
PEG Ratio 20.64
RHHVF's PEG Ratio is ranked lower than
94% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. RHHVF: 20.64 )
Ranked among companies with meaningful PEG Ratio only.
RHHVF' s PEG Ratio Range Over the Past 10 Years
Min: 0.24  Med: 3.15 Max: 23.21
Current: 20.64
0.24
23.21
Shiller PE Ratio 21.75
RHHVF's Shiller PE Ratio is ranked higher than
78% of the 164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.73 vs. RHHVF: 21.75 )
Ranked among companies with meaningful Shiller PE Ratio only.
RHHVF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.32  Med: 23.54 Max: 34.29
Current: 21.75
18.32
34.29
Current Ratio 1.27
RHHVF's Current Ratio is ranked lower than
79% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. RHHVF: 1.27 )
Ranked among companies with meaningful Current Ratio only.
RHHVF' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.33 Max: 3.75
Current: 1.27
1.19
3.75
Quick Ratio 0.92
RHHVF's Quick Ratio is ranked lower than
79% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. RHHVF: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
RHHVF' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.93 Max: 3.22
Current: 0.92
0.86
3.22
Days Inventory 178.94
RHHVF's Days Inventory is ranked lower than
77% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. RHHVF: 178.94 )
Ranked among companies with meaningful Days Inventory only.
RHHVF' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 178.94
143.33
186.16
Days Sales Outstanding 63.22
RHHVF's Days Sales Outstanding is ranked higher than
61% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. RHHVF: 63.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHVF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.14  Med: 73.14 Max: 84.09
Current: 63.22
63.14
84.09
Days Payable 76.14
RHHVF's Days Payable is ranked higher than
53% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. RHHVF: 76.14 )
Ranked among companies with meaningful Days Payable only.
RHHVF' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 76.14
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.21
RHHVF's Dividend Yield % is ranked higher than
81% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. RHHVF: 3.21 )
Ranked among companies with meaningful Dividend Yield % only.
RHHVF' s Dividend Yield % Range Over the Past 10 Years
Min: 1.06  Med: 2.95 Max: 4.55
Current: 3.21
1.06
4.55
Dividend Payout Ratio 0.73
RHHVF's Dividend Payout Ratio is ranked lower than
81% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. RHHVF: 0.73 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RHHVF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.6 Max: 0.78
Current: 0.73
0.31
0.78
3-Year Dividend Growth Rate 3.30
RHHVF's 3-Year Dividend Growth Rate is ranked lower than
64% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. RHHVF: 3.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RHHVF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -75.7  Med: 11.15 Max: 27.3
Current: 3.3
-75.7
27.3
Forward Dividend Yield % 3.19
RHHVF's Forward Dividend Yield % is ranked higher than
78% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. RHHVF: 3.19 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.02
RHHVF's 5-Year Yield-on-Cost % is ranked higher than
78% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. RHHVF: 4.02 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RHHVF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.33  Med: 3.69 Max: 5.7
Current: 4.02
1.33
5.7
3-Year Average Share Buyback Ratio -0.10
RHHVF's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. RHHVF: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHVF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -364.1  Med: 0 Max: 78.5
Current: -0.1
-364.1
78.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 369.88
RHHVF's Price-to-Tangible-Book is ranked lower than
100% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. RHHVF: 369.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RHHVF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.06  Med: 7.43 Max: 1920.4
Current: 369.88
0.06
1920.4
Price-to-Intrinsic-Value-Projected-FCF 1.67
RHHVF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. RHHVF: 1.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RHHVF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.12  Med: 1.72 Max: 3.89
Current: 1.67
1.12
3.89
Price-to-Median-PS-Value 1.08
RHHVF's Price-to-Median-PS-Value is ranked higher than
57% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. RHHVF: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RHHVF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.02 Max: 212.25
Current: 1.08
0.02
212.25
Price-to-Graham-Number 19.33
RHHVF's Price-to-Graham-Number is ranked lower than
99% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.26 vs. RHHVF: 19.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RHHVF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.74  Med: 3.57 Max: 636.76
Current: 19.33
0.74
636.76
Earnings Yield (Greenblatt) % 5.92
RHHVF's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. RHHVF: 5.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RHHVF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5  Med: 7.2 Max: 13.4
Current: 5.92
5
13.4
Forward Rate of Return (Yacktman) % 6.42
RHHVF's Forward Rate of Return (Yacktman) % is ranked lower than
56% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.75 vs. RHHVF: 6.42 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RHHVF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.5  Med: 8.9 Max: 62.3
Current: 6.42
4.5
62.3

More Statistics

Revenue (TTM) (Mil) $50,877
EPS (TTM) $ 11.23
Beta0.63
Short Percentage of Float0.00%
52-Week Range $216.45 - 270.00
Shares Outstanding (Mil)851.93

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 55,148 60,533
EPS ($) 15.84 17.58
EPS without NRI ($) 15.84 17.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.30%
Dividends per Share ($) 8.49 9.13
» More Articles for RHHVF

Headlines

Articles On GuruFocus.com
A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017 
Blake Insomnia CEO Dreams of Improving Sleep Jan 04 2017 
Roche's Leukemia Drug Approved for Next Step in Europe Dec 11 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee Oct 14 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 

More From Other Websites
Roche MS drug Ocrevus approved by FDA after 3-month delay Mar 28 2017
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA Mar 24 2017
Dow's Merck Swipes Immuno-Oncology Share From Heavyweight Rivals Mar 22 2017
Should Value Investors Pick Roche Holding (RHHBY)? Mar 22 2017
Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report? Mar 17 2017
It’s time to vaccinate your investments against a deadly bird flu Mar 14 2017
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi Mar 06 2017
5 FDA Decisions to Watch Out for in Mar 2017 Mar 06 2017
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug Mar 03 2017
[$$] Actelion Began in a Garage—Now Its Founding Couple Has $1 Billion and a New Biotech Firm Mar 03 2017
Roche Shares Boosted by Cancer Drug Trial Success Mar 03 2017
Roche's New Drugs May Protect its Old Ones Mar 02 2017
[$$] Actelion's Founders Start New Biotech, With J&J's Backing Mar 02 2017
Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win Mar 02 2017
Roche's Aphinity Succeeds, Boosting Breast-Cancer Business Mar 02 2017
Big Pharma Is Losing a Fortune Trying to Cure Alzheimer's Mar 01 2017
Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team Feb 27 2017
Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals Feb 23 2017
Roche says Phase II trial supports twin treatment for kidney cancer Feb 18 2017
These Are The First Immune-System Cancer Drugs OK'd By FDA Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)